RaDaR ST uses patient-specific, tumor-informed panels to detect trace amounts of tumor DNA in blood, often before recurrence is visible on imaging. The assay combines whole-exome sequencing with advanced bioinformatics to track up to 48 tumor-specific variants with a limit of detection at 95% probability (LOD95) of 11 ppm, offering high sensitivity and specificity.* FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision m ...

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology. ...

NeoGenomics (NEO) has been on a downward spiral lately with significant selling pressure. After declining 22.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

Core Insights - NeoGenomics, Inc. reported a full-year diluted earnings per share (EPS) of -$0.84, which missed estimates, but exceeded revenue expectations with a full-year revenue of $727 million, reflecting a 10% increase from $661 million the prior year [3][4] - In the fourth quarter, the company achieved an adjusted diluted EPS of $0.06, surpassing the Zacks Consensus Estimate of $0.04, indicating a 50% earnings surprise [3][4] - Over the past four quarters, NeoGenomics has exceeded consensus adjusted EPS estimates three times, demonstrating its ability to outperform market expectations [4][5] Financial Performance - The revenue for the quarter ending December 2025 was $190 million, exceeding the Zacks Consensus Estimate by approximately 0.9% to 1.1%, and showing a significant increase from the $172 million reported in the same period the previous year [4] - The company has surpassed consensus revenue estimates twice in the last four quarters, showcasing consistent revenue growth [5] Market Valuation and Liquidity - NeoGenomics has a negative trailing price-to-earnings (P/E) ratio of approximately -12.5 and a price-to-sales ratio of around 2.06, indicating that the market values its sales at about $2.06 for every dollar of sales [2][5] - The enterprise value to sales ratio is approximately 2.3, reflecting the company's total valuation relative to its sales [5] - With a current ratio of 4.26, NeoGenomics maintains a strong liquidity position, indicating its ability to cover current liabilities with its assets [2][5]

Financial Performance - Revenue increased by 10.1% compared to 2024[258] - Adjusted EBITDA rose by 9.5% or $3.7 million to $43.4 million compared to 2024[258] - Consolidated revenue for the year ended December 31, 2025, was $727.3 million, representing a 10.1% increase from $660.6 million in 2024, primarily driven by increased test volumes and strategic reimbursement initiatives[284] - The net loss for 2025 was $108.0 million, compared to a net loss of $78.7 million in 2024, with a basic net loss per share of $(0.84)[307] - For the year ended December 31, 2025, NeoGenomics reported a net loss of $108.0 million, compared to a net loss of $78.7 million in 2024, reflecting a year-over-year increase of 37.3% in losses[312] - Adjusted EBITDA for 2025 was $43.4 million, an increase of 9.0% from $39.6 million in 2024, indicating improved operational performance despite the net loss[312] Expenses and Costs - Cost of revenue for 2025 was $413.0 million, up 11.5% from $370.5 million in 2024, with gross profit of $314.3 million and a gross profit margin of 43.2%, down from 43.9% in 2024[286][288] - General and administrative expenses increased by $13.6 million to $273.3 million in 2025, accounting for 37.6% of revenue, compared to 39.3% in 2024[290] - Research and development expenses rose 19.0% to $37.1 million in 2025, representing 5.1% of revenue, driven by increased compensation and benefits costs[292] - Sales and marketing expenses increased by $7.4 million to $92.0 million in 2025, accounting for 12.6% of revenue, compared to 12.8% in 2024[295] - Impairment charges for 2025 were $27.8 million, including an $11.4 million impairment on InVisionFirst®-Lung intangible assets and a $15.9 million impairment on Trapelo's assets[300] Cash Flow and Liquidity - Cash provided by operating activities decreased to $5.2 million in 2025 from $7.0 million in 2024, a decline of 25.7% primarily due to higher cash used from operating results[313] - Cash used in investing activities was $12.3 million in 2025, a significant shift from cash provided of $12.9 million in 2024, driven by a $33.9 million decrease in proceeds from marketable securities[314] - Cash used in financing activities surged to $200.3 million in 2025, compared to cash provided of $4.6 million in 2024, primarily due to the repayment of the 2025 Convertible Notes[315] - As of December 31, 2025, NeoGenomics had $159.6 million in cash and cash equivalents, sufficient to support operational liquidity needs for at least the next 12 months[316] Strategic Initiatives - The acquisition of Pathline was completed in April 2025[258] - The company aims to drive targeted product launches in therapy selection and MRD through its launch excellence program[259] - Continued expansion into the community oncology market is planned, leveraging established strategic positions with community hospitals[259] - The company expects to maintain operational efficiency through automation and process improvements[259] - The company is focused on enhancing its test menu and driving down testing costs through investments in technology and automation[255] - The company anticipates an increase in research and development expenditures as it continues to invest in innovation projects and new tests[293] - The company anticipates continued growth opportunities in key markets despite an increasingly uncertain macroeconomic environment in fiscal year 2026[320] Regulatory and Market Environment - The FDA's evolving regulatory framework for Laboratory Developed Tests (LDTs) may impact compliance obligations and costs[263] - NeoGenomics is a leading provider of Heme oncology diagnostic testing and solid tumor NGS testing solutions in the U.S.[254] - The company operates under a single segment encompassing a comprehensive range of oncology diagnostic services[265] - NeoGenomics has operations in the UK, exposing it to foreign currency exchange risks, primarily in British Pounds, but currently does not hedge these risks[324] - The company issued $345.0 million in 2028 Convertible Notes with a fixed annual interest rate of 0.25%, which mitigates economic interest rate exposure[323] Interest Income and Expense - Interest income decreased by 50.8% to $9.1 million in 2025, primarily due to a reduction in the average balance of invested cash and lower interest rates[302] - Interest expense decreased by 43.3% to $3.8 million in 2025, reflecting the maturity and settlement of the Company's 2025 Convertible Notes[305]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $190 million, representing an 11% year-over-year growth, while full-year revenue reached $727 million, a 10% increase over 2024 [8][23] - Adjusted gross profit improved by $5.8 million, or 7% year-over-year, with adjusted EBITDA at $13.4 million, up 10% [20] - Cash flow from operations was positive at $1 million for Q4, with total cash at $160 million, slightly down from Q3 [22] Business Line Data and Key Metrics Changes - Clinical business revenue increased by 16% year-over-year in Q4, driven by effective commercial strategies and growth in test volumes [8][20] - NGS revenue grew by 23% year-over-year, accounting for about one-third of total clinical revenue [21] - Non-clinical revenue declined by over 25% in Q4 and 24% for the full year, aligning with revised expectations [20][23] Market Data and Key Metrics Changes - The company holds a leadership position in the hematology testing market with over 25% market share [10] - Approximately 40% of active pathologists and oncologists ordered five or more tests from the company during the year, indicating significant market penetration [11] Company Strategy and Development Direction - The company aims to drive strategic, profitable growth through continued expansion of NGS revenues and market penetration for the PanTracer family and RaDaR ST [29] - The focus is on enhancing customer workflows and productivity through investments in technology and automation [29] - The company plans to expand its sales force to support the launch of RaDaR ST and penetrate the head and neck market [14][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance for 2026, expecting revenues between $793 million and $801 million, with a focus on RaDaR ST and PanTracer Liquid contributions [25][27] - The company anticipates modest erosion in the pharma business for 2026, with a return to growth expected in 2027 [70][74] Other Important Information - The company is preparing for a full clinical launch of the RaDaR ST MRD assay, with expectations for revenue growth to accelerate in 2027 and beyond [14][27] - The integration of a common LIMS system is expected to enhance operational efficiencies and customer experience, with more pronounced benefits anticipated in 2027 and 2028 [59][63] Q&A Session Summary Question: Can you provide specifics on the RaDaR ST launch and sales rep expansion? - Management confirmed the full launch of RaDaR ST is planned for the end of the month, focusing on head and neck and breast cancer indications, with an initial sales force expansion targeting ENTs [34][38] Question: What is the impact of exiting low-value business on clinical volume? - Management indicated that exiting low-value contracts is expected to lead to higher AUP growth, with a focus on therapy selection and MRD driving overall revenue growth [45][46] Question: What are the expectations for the pharma business in 2026? - Management anticipates modest erosion in the pharma business for 2026, with a return to growth expected in 2027, driven by RaDaR ST [70][74] Question: How is the sales force performing after recent expansions? - The sales force is expected to contribute positively to growth, with oncology sales specialists focusing on therapy selection and supporting the RaDaR ST launch [90]

NeoGenomics (NasdaqCM:NEO) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAbhishek Jain - EVP of Finance and Incoming CFOJeff Sherman - CFOKendra Webster - VP of Investor RelationsTony Zook - CEOWarren Stone - Chief Commercial OfficerConference Call ParticipantsAndrew Brackman - Equity Research AnalystAndrew Cooper - Equity Research AnalystBill Bonello - Equity Research AnalystDan Brennan - Equity Research AnalystDavid Westenberg - Equity Research AnalystMark Massaro - Equity Resear ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $190 million, representing an 11% year-over-year growth [6] - Full year total revenue reached $727 million, a 10% increase over 2024 [24] - Adjusted gross profit improved by $5.8 million, or 7% over the prior year, with adjusted EBITDA at $13.4 million, up 10% [20] - Cash flow from operations was positive at $1 million for Q4, with total cash at $160 million [22] Business Line Data and Key Metrics Changes - Clinical business revenue increased by 16% year-over-year in Q4, driven by effective commercial strategies [6] - NGS revenue grew by 23% year-over-year, accounting for about one-third of total clinical revenue [21] - Non-clinical revenue declined by over 25% in Q4, with a full year decline of 24% [20][24] Market Data and Key Metrics Changes - The company holds a leadership position in the hematology testing market with over 25% market share [9] - Approximately 40% of active pathologists and oncologists ordered five or more tests from NeoGenomics during the year [10] Company Strategy and Development Direction - The company aims to drive growth through the expansion of NGS revenues and market penetration for the PanTracer family and RaDaR ST [29] - A focus on strategic, profitable growth is emphasized, with investments in sales and marketing and R&D for new product initiatives [28] - The company is preparing for a full clinical launch of the RaDaR ST MRD assay, which is expected to enhance market opportunities [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance for 2026, expecting revenues between $793 million and $801 million [26] - The company anticipates modest revenue contributions from RaDaR ST in 2026, with growth expected to accelerate in 2027 and beyond [13] - Management acknowledged potential impacts from extreme weather on Q1 volumes but remains optimistic about overall growth [27] Other Important Information - The company has launched five NGS products since March 2023, contributing significantly to revenue growth [18] - The acquisition of PathLine is expected to provide operational efficiencies and synergies that will be accretive to profitability [10] Q&A Session Summary Question: Can you provide specifics on the RaDaR ST launch and sales rep focus? - Management confirmed the full launch of RaDaR ST is planned for the end of the month, focusing on head and neck and subsets of breast cancer [34] - The initial sales force expansion will target the head and neck market, with plans to add more reps for future indications [36] Question: What is the impact of exiting low-value business on clinical volume? - Management indicated that exiting low-value contracts will lead to higher AUPs and better margins, with expectations for AUP growth in the upper single-digit range [44] Question: Can you clarify guidance for the core clinical business? - Management expects the core clinical business to grow at about 10%, factoring in the full year of PathLine and the impact of exiting low-value contracts [52] Question: What is the framework for LIMS integration this year? - The company is migrating to a common LIMS system, with benefits expected to materialize in 2027, while optimizing workflows for efficiency [57] Question: What is the potential for continued ASP growth? - Continued growth in AUP is anticipated, driven by the shift into NGS and managed care pricing increases [84]

NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +57.90%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post earnings of $0.02 per share when it actually produced earnings of $0.03, delivering a surprise of +50%.Over th ...

Q4 and FY 2025 Financial Results February 17, 2026 Nasdaq: NEO Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe, ...